2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6258 Curability should be universal: Association between Medicaid expansion and survival in classic Hodgkin lymphoma

Nikki Verma, MD, German Stemmelin, MD2, Qianqian Liu, PhD3, Joel Michalek, PhD4, Adolfo Diaz Duque, MD, MSc5
1 University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
2 Hospital Británico de Buenos Aires, Buenos Aires, Argentina
3 University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
4 University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
5 University of Texas Health Science Center San Antonio, San Antonio, Texas, United States

Background

Classical Hodgkin lymphoma (cHL) is a highly curable hematologic malignancy, with 5-year relative survival exceeding 89%. Despite these favorable outcomes, uninsured patients and Medicaid beneficiaries with cHL historically experienced worse survival than their privately insured counterparts. The Affordable Care Act (ACA) Medicaid expansion substantially increased insurance coverage and has been associated with improved outcomes across multiple malignancies. However, its effect on survival among patients with cHL has not been well characterized. Using a difference-in-differences design, we evaluated the impact of Medicaid expansion on overall survival among patients with cHL in the National Cancer Database (NCDB).

Methods

Adult patients diagnosed with cHL between 2004 and 2023 were identified from the NCDB. Patients were stratified according to residence in Medicaid expansion versus non-expansion states and by diagnosis before (2004-2013) or after (2014-2023) ACA Medicaid expansion. Baseline demographic, socioeconomic, and clinical characteristics were compared using chi-square and Wilcoxon rank-sum tests. Overall survival was estimated using adjusted Kaplan-Meier methods after balancing for baseline covariates, with differences assessed by log-rank testing.

Results

A total of 55,204 patients with cHL were identified, including 26,764 (49%) diagnosed before Medicaid expansion and 28,440 (52%) after implementation. Overall, 41,767 (76%) patients resided in Medicaid expansion states and 13,437 (24%) in non-expansion states. Before 2014, 20,509 (77%) patients resided in expansion states compared with 6,255 (23%) in non-expansion states; after 2014, 21,258 (75%) and 7,182 (25%), respectively.

Patients diagnosed after ACA implementation were older (median 61 vs. 58 years, P<0.001), more frequently Hispanic (10.7% vs. 7.8%, P<0.001), and more likely to receive treatment at academic centers (56% vs. 54%, P<0.001). Government-sponsored insurance increased from 43% to 51%, while uninsured status decreased from 5% to 4% (P<0.001 for both). Median household income also increased significantly over time (P<0.001). Patients diagnosed after 2014 more commonly presented with stage IV disease (29 % vs. 21%), whereas stage I disease declined (13% vs. 17%; P<0.001).

Across the entire study period, patients residing in Medicaid expansion states demonstrated more favorable socioeconomic characteristics. They were significantly less likely to be uninsured (3% vs. 8%, P<0.001), more likely to receive care at academic centers (56% vs. 52%, P<0.001), and more frequently resided in higher-income communities (37% vs. 22%, P<0.001). Hispanic patients represented 8% of expansion-state cohorts compared with 14% in non-expansion states (P<0.001).

Adjusted Kaplan-Meier analyses demonstrated superior overall survival (OS) among patients residing in Medicaid expansion states both before ACA implementation (log-rank P=0.0004) and after implementation (log-rank P<0.0001). In Medicaid expansion states, estimated 2-, 5-, and 10-year OS improved from 77%, 69%, and 57% before expansion to 81%, 73%, and 59% after expansion. Corresponding survival estimates in non-expansion states improved from 76%, 67%, and 55% to 78%, 70%, and 56 %, respectively. Despite improvements observed in both eras, patients residing in Medicaid expansion states consistently demonstrated superior adjusted survival throughout follow-up.

Conclusions

Patients with cHL residing in Medicaid expansion states experienced significantly superior adjusted OS both before and after ACA implementation. Although survival improved nationally during the contemporary treatment era, likely reflecting advances in diagnosis, supportive care, and therapy, the survival advantage associated with Medicaid expansion states persisted despite an older patient population and a greater proportion of advanced-stage disease after 2014. These findings highlight the continued importance of healthcare access and socioeconomic factors in influencing outcomes even in highly curable hematologic malignancies and support further causal analyses evaluating the independent contribution of Medicaid expansion to survival.

 

Nikki Verma, MD: No relevant conflicts of interest to declare.